DAFTAR PUSTAKA

1.

Barr R. et al., 2006. Pediatric Oncology in Countries with Limited

Resources. In: Arora R.S., Eden T.O.B., Kapoor G., 2009. Epidemiology
of childhood cancer in India. Indian Journal of Cancer October-December
2009; 46 (4): 264.

2. Ries L. et al,. 2008. Cancer Incidence and survival among children and
adolescents. In: Arora R.S., Eden T.O.B., Kapoor G., 2009. Epidemiology
of childhood cancer in India. Indian Journal of Cancer October-December
2009; 46(4): 264.
3. Kementerian Kesehatan Republik Indonesia, 2009. Aktivitas Fisik dan
Diet Seimbang Mencegah Kanker. Availabe from: . [ Updated: 20 March
2009].
http://www.depkes.go.id/index.php/berita/press-release/170aktivitas-fisikdan-diet-seimbang-mencegah-kanker.html
4. Steele RW. Managing Infection in Cancer Patients and Other
Immunocompromised Children. The Ochsner Journal 2012:12:202210.
5. Paul M, Yahav D, Bivas A, Fraser A, Leibovici L. Anti-pseudomonal betalactams for the initial, empirical, treatment of febrile neutropenia:
comparison of beta-lactams (abstract). Cochrane Database of Systematic
Reviews 2010.
6. van Dalen EC, Mank A, Leclercq E, Mulder RL, Davies M, Kersten MJ,
van de Wetering MD. Low bacterial diet versus control diet to prevent
infection in cancer patients treated with chemotherapy causing episodes of
neutropenia (abstract). Cochrane Database of Systematic Reviews 2012.
7. Erbey F, Bayram I, Yilmaz S, Tanyeli A. Meropenem Monotherapy as an
Empirical Treatment of Febrile Neutropenia in Childhood Cancer Patients.
Asian Pacific Journal of Cancer Prevention 2010:11; 123-6
8. Livadiotti S, Milano GM, Serra A, Folgori L, Jenkner A, Castagnola E,
Cesaro S, et al. A survey on hematology-oncology pediatric AIEOP
centers: prophylaxis, empirical therapy and nursing prevention procedures
of infectious complications. haematologica | 2012; 97(1):147-50
9. Rena RA, Suega K, Bakta IM. Pola Kepekaan Bakteri Pada Pasien
Keganasan Hematologi Di Rsup Sanglah Denpasar. J Peny Dalam 2010,:
11 2010:104-9
10. Gatta G. et al., 2005. Childhood Cancer Survival Trends in Europe: A
EUROCARE Working Group Study. Journal of Clinical Oncology; 23(16):
3742-3744.

11. Qaddoumi I. et al., 2008. Closing the survival gap: Implementation of

medullablastoma protocols in a low-income country through a twinning
program. In: Arora R.S., Eden T.O.B., Kapoor G., 2009. Epidemiology of
childhood cancer in India. Indian Journal of Cancer October-December
2009; 46 (4): 264.
12. Harif M. et al., 2008. Treatment of B-cell lymphoma with LMB modified
protocols in Africa. In: Arora R.S., Eden T.O.B., Kapoor G., 2009.
Epidemiology of childhood cancer in India. Indian Journal of Cancer
October-December 2009; 46 (4): 264.
13. Lynn A. Gloeckler Ries. CHILDHOOD CANCER MORTALITY. SEER
Pediatric Monograph. 165-170.
14. Metzger M.L. et al., 2003. Outcome of childhood acute lymphoblastic
leukemia in resource-poor countries. In: Mostert S., Sitaresmi M.N.,
Gundy C.M., Sutaryo, Veerman A.J.P., 2006. Influence of Sociaeconomic
Status on Childhood Acute Lymphoblastic Leukemia Treatment in
Indonesia. Pediatrics 2006; 118(6): e1601.
15. Mostert S., Sitaresmi M.N., Gundy C.M., Sutaryo, Veerman A.J.P., 2006.
Influence of Sociaeconomic Status on Childhood Acute Lymphoblastic
Leukemia Treatment in Indonesia. Pediatrics 2006; 118(6): e1601.
16. -----. Guidelines for the initial treatment of neutropenic fever in adult highrisk
17. -----. London regional cancer program febrile neutropenia. London Health
Sciences Center.
18. Heather L, Gerald RD. Outpatient management of febrile neutropenia:
concern for the future. J Support Oncol 2008;6:217-218.
19. Antonius H, Badriul P, SetyoH, Handryastuti, Salamia Nikmah, Idris,
Ellen P, et al. Pedoman Pelayanan Medis Ikatan Dokter Anak Indonesia.
Jakarta: Badan Penerbit Ikatan Dokter Anak Indonesia, 2011.
20. Mancini N, Clerici D, Diotti R, Perotti M,Ghidoli N, De Marco D, et al.
Molecular diagnosis of sepsis in neutropenic patients with haematological
malignancies. Journal of Medical Microbiology 2008;57:601-4.
21. Danai PA, Moss M, David MM, Martin GS. The epidemiology of sepsis in
patients with malignancy. Journal of Clinical Oncology 2000;18(21):36908.
22. Kannangara S. Management of febrile neutropenia. Community Oncology
2006;3:585-591

23. Snezana B. Treatment of a febrile neutropenic patient. Arch Oncol

2004;12:179-181.
24. Gert JT et al. Cefpirome as empirical treatment for febrile neutropenia in
patients with hematologic malignancies. Heamatologica 2005;90:10051006.
25. Soad A, Ramesh P, Ketan B, Bipin S. Febrile neutropenia in patient with
acute leukemia with long-term central venous access in Kuwait: Microbial
spectrum, outcome and catheter management. Med Principles Pract
2000;9:35-41.
26. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T et
al. 2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic
Patients with Cancer. CID 2002 ;34 : 730-751.
27. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA,
Raad II, Rolston KV, et al. Clinical Practice Guideline for the Use of
Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update
by the Infectious Diseases Society of America. CID 2011:52:e56-e63
28. Wade JC. Viral infection in patients with haematological malignancies.
Haematology 2006;p.368-74.
29. Favero AD, Bucaneve G, Furno P. Choice of emperical therapy and
prophylaxis. The Hematology Journal 2004;5:S53-8.
30. Barone A. Antibacterial prophylaxis in neutropenic children with cancer.

Pediatric Reports 2011; 3:9-10